These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34743655)

  • 1. The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [
    Lu J; Bian Y; Zhang H; Tang D; Tian X; Zhou X; Xu Z; Xiong Y; Gu Z; Yu Z; Wang T; Ding J; Yu Q; Ding J
    Xenobiotica; 2022 Jan; 52(1):38-45. PubMed ID: 34743655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition study of the novel dipeptidyl peptidase 4 inhibitor cetagliptin in rats.
    Lu J; Hao Y; Zhang F; Pan H; Ding J; Yu Q; Wang T
    Xenobiotica; 2022 May; 52(5):468-475. PubMed ID: 35708192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
    Wang L; Lu J; Zhou S; Zhao Y; Xie L; Zhou C; Chen J; Ding S; Xie D; Ding J; Yu Q; Shen H; Hao G; Shao F
    Clin Drug Investig; 2021 Nov; 41(11):999-1010. PubMed ID: 34655432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.
    Lu J; Wang L; Zhou S; Zhou C; Xie L; Chen J; Tang D; Tian X; Xie D; Ding J; Wang T; Yu Q; Ding J; Shao F
    Br J Clin Pharmacol; 2022 Jun; 88(6):2946-2958. PubMed ID: 34965609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Bian YC; Meng J; Hu T; Ma S; Huang CR; Zhang FY; Wu QH; Zhang H; Chen XY; Miao LY
    Diabetes Obes Metab; 2024 Jul; 26(7):2860-2868. PubMed ID: 38646838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
    Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
    Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
    Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
    Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
    Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
    Tiseo PJ; Perdomo CA; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, Metabolism, and Excretion of [
    Xie L; Xu Y; Liu W; Zhou C; Guo L; Zhou S; Zhang C; Chen J; Zhu B; Ding S; Li H; Zhang L; Wang L; Xu L; Shao F; Wang L
    Clin Pharmacol Drug Dev; 2024 Oct; 13(10):1115-1122. PubMed ID: 39101494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
    Chen N; Wen L; Lau H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excretion balance and pharmacokinetics following a single oral dose of [
    Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
    Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M
    Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects.
    Vernillet L; Greene SA; Kim HW; Melnick SM; Glenn K
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):513-522. PubMed ID: 32301064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.